B.Riley FBR analyst Andrew D’silva maintained a Hold rating on Oramed Pharmaceuticals (ORMP) yesterday and set a price target of $5. The company’s shares opened today at $3.50, close to its 52-week low of $2.97.
D’silva said:
“Oramed Pharmaceuticals (ORMP) filed its 10-Q for 1Q19 (November quarter) on Monday, 1/14. The company does not host a conference call. ORMP’s top-line/EPS came in at $0.7M/$(0.25), compared to our/consensus estimates of $0.6M/$(0.20) and $0.6M/$(0.19), respectively. Revenues were tied to milestone payments received through ORMP’s out-license agreement with Technologies (HTIT). ORMP’s EPS miss was primarily due to higher R&D expense than our estimates called for. Meanwhile, ORMP remains well capitalized to meet its near-term objectives and exited 1Q19 with $42.8M in cash/investments, no debt, and a current ratio of 7.1:1.0.”
According to TipRanks.com, D’silva is a 4-star analyst with an average return of 7.9% and a 37.0% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc., EyePoint Pharmaceuticals Inc, and Imprimis Pharmaceuticals.
Currently, the analyst consensus on Oramed Pharmaceuticals is a Moderate Buy with an average price target of $15.
See today’s analyst top recommended stocks >>
Based on Oramed Pharmaceuticals’ latest earnings release for the quarter ending August 31, the company reported a quarterly GAAP net loss of $2.93 million. In comparison, last year the company had a GAAP net loss of $2.53 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in Jerusalem, Israel.
